VSTMVerastem, Inc.

Healthcare

$10.02+27% 1Y

$10.02

$3.4552 weeks$10.64

Price

+27%1Y

End-of-day closes, not the intraday tick.

Mostly good, one thing to check: safety

Quality strong, a flag to check, growing in the filings, the market undecided.

RyuScore 17 of 100: see how it is built

P/En/a

Market value$907.4M

1 year+27%

5 years-70%

Charts

As reported to the SEC, without any scoring.

Verastem, Inc. (VSTM) reported revenue of $40M in Q2 2026 (quarter ended Jun 30, 2026), up 1775% from the same quarter a year earlier. That came with net loss of $35M. For the full year FY2025, revenue was $31M (+209% year on year) and net income −$209M. The next results filing is expected around Feb 3, 2027, the same week as a year ago.

What the company said

The company's own words from its current reports to the SEC, newest first

Oct 14, 2026On October 14, 2026, Verastem, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named in Schedule I thereto (the “Underwriters”), relating to the underwritten offering, issuance …Other event · Form 8-K
Oct 14, 2026Chief Executive Officer Transition On October 12, 2026, Daniel W. Paterson notified the Board of Directors (the “Board”) of the Company of his decision to retire as President and Chief Executive Officer of the Company, effective January 1, 2027 (the “Effective Date”)Earnings release · Form 8-K
Aug 7, 2026On August 6, 2026 (the “Amendment Closing Date”), Verastem, Inc., (the “Company”) entered into Amendment No. 3 (the “Amendment”) to that certain Note Purchase Agreement, dated as of January 13, 2025 (the “Original Closing Date”), as previously amended by Amendment No. 1 dated as of October 31, 2025 and Amendment No. 2 …Material agreement entered · Form 8-K